Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

Journal of Clinical Investigation

Volumn 112, Issue 7, 2003, Pages 1029-1036

  Flood Page, Patrick ^a   Menzies Gow, Andrew ^a   Phipps, Simon ^a   Ying, Sun ^b   Wangoo, Arun ^a   Ludwig, Mara S ^c   Barnes, Neil ^d   Robinson, Douglas ^a   Kay, A Barry ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; LUMICAN; MEPOLIZUMAB; MESSENGER RNA; MONOCLONAL ANTIBODY; PROCOLLAGEN; TENASCIN; TRANSFORMING GROWTH FACTOR BETA1; COLLAGEN TYPE 3; KERATAN SULFATE; PROTEOCHONDROITIN SULFATE; SCLEROPROTEIN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ASTHMA; ARTICLE; ASTHMA; BASEMENT MEMBRANE; BRONCHUS BIOPSY; BRONCHUS MUCOSA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EOSINOPHIL; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LUNG LAVAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BRONCHUS; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ASTHMA; BASEMENT MEMBRANE; BRONCHI; COLLAGEN TYPE III; DOUBLE-BLIND METHOD; EOSINOPHILS; EXTRACELLULAR MATRIX PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-5; KERATAN SULFATE; PROTEOCHONDROITIN SULFATES; RNA, MESSENGER; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85047693849     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI17974     Document Type: Article

References (52)

1. Bousquet, J., Jeffery, P.K., Busse, W.W., Johnson, M., and Vignola, A.M. 2000. Asthma. From bronchoconstriction to airways in flammation and remodeling. Am. J. Respir. Crit. Care Med. 161:1720-1745.
2. Roche, W.R., Beasley, R., Williams, J.H., and Holgate, S.T. 1989. Sub-epithelial fibrosis in the bronchi of asthmatics. Lancet. 1:520-524.
3. Wilson, J.W., and Li, X. 1997. The measurement of reticular basement membrane and submucosal collagen in the asthmatic airway. Clin. Exp. Allergy. 27:363-371.
4. Jeffery, P.K., et al. 1992. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am. Rev. Respir. Dis. 145:890-899.
5. Laitinen, A., et al. 1997. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am. J. Respir. Crit. Care Med. 156:951-958.
6. Huang, J., Olivenstein, R., Taha, R., Hamid, Q., and Ludwig, M. 1999. Enhanced proteoglycan deposition in the airway wall of atopic aschmatics. Am. J. Respir. Crit. Care Med. 160:725-729.
7. Murphy-Ullrich, J.E. 2001. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J. Clin. Invest. 107:785-790.
8. Anwar, A.R., Moqbel, R., Walsh, G.M., Kay, A.B., and Wardlaw A.J. 1993. Adhesion to fibronectin prolongs eosinophil survival. J. Exp. Med. 177:839-843.
9. Ebina, M., Takahashi, T., Chiba, T., and Motomiya, M. 1993. Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study. Am. Rev. Respir. Dis. 148:720-726.
10. Ordonez, C.L., et al. 2001. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am. J. Respir. Crit. Care Med. 163:517-523.
11. Li, X., and Wilson, J.W. 1997. Increased vascularity, of the bronchial mucosa in mild asthma. Am. J. Respir. Crit. Care Med. 156:229-233.
12. Wenzel, S.E., et al. 1999. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 160:1001-1008.
13. Todd, R., et al. 1991. The eosinophil as a cellular source of transforming growth factor alpha in healing cutaneous wounds. Am. J. Pathol. 138:1307-1313.
14. Wong, D.T., et al. 1993. Sequential expression of transforming growth factors alpha and beta 1 by eosinophils during cutaneous wound healing in the hamster. Am. J. Pathol. 143:130-142.
15. Noguchi, H., Kephart, G.M., Colby, T.V., and Gleich, G.J. 1992. Tissue eosinophilia and eosinophil degtanulation in syndromes associated with fibrosis. Am. J. Pathol. 140:521-528.
16. Wong, D.T., et al. 1990. Human eosinophils express transforming growth factor alpha. J. Exp. Med. 172:673-681.
17. Wong, D.T., et al. 1991. Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1. Blood. 78:2702-2707.
18. Hoshino, M., Takahashi, M., and Aoike, N. 2001. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J. Allergy Clin. Immunol. 107:295-301.
19. Okada, S., Kita, H. George, T.J., Gleich, G.J., and Leiferman, K.M. 1997. Migration of eosmophils through basement membrane components in vitro: role of matrix metalloproteinase-9. Am. J. Respir. Cell Mol. Biol. 17:519-528.
20. Levi-Schaffer, F., et al. 1999. Human eosinophils regulate human lung-and skin-derived fibroblast properties in vitro a role for transforming growth factor beta (TGF-beta). Proc. Natl. Acad. Sci. U. S. A. 96:9660-9665.
21. Schmid-Grendelmeier, P., et al. 2002. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J. Immunol. 169:1021-1027.
22. Powell, D.W., et al. 1999. Myofibroblasts. I. Paracrine cells important in health and disease. Am. J. Physiol. 277:C1-C9.
23. Paakko, P., Kaarteenaho-Wiik, R., Pollanen, R., and Soini, Y. 2000. Tenascin MPNA expression at the foci of recent injury in usual interstitial pneumonia. Am. J. Respir. Crit. Care Med. 161:967-972.
24. Phipps, S., et al. 2002. The relationship between allergen-induced tissue eosinophilia and markers of repair and remodeling in human atopic skin. J. Immunol. 169:4604-4612.
25. Sanderson, C.J. 1992. Interleukin-5, eosinophils, and disease. Blood. 79:3101-3109.
26. Sehmi, R., et al. 1992. Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood. 79:2952-2959.
27. Rothenberg, M.E., et al. 1989. IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cycotoxicity. J. Immunol. 143:2311-2316.
28. Leckie, M.J., et al. 2000. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 356:2144-2148.
29. Kips, J.C., et al. 2003. The effect of SCH55700, a humanized, anti-hILS antibody in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 167:1655-1659.
30. Flood-Page, P.T., Menzies-Gow, A.N., Kay, A.B., and Robinson, D.S. 2003. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167:199-204.
31. Liu, L.Y., et al. 2002. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J. Immunol. 169:6459-6466.
32. Gregory, G., et al. 2003. Differential regulation of human eosinophil IL-3, IL-5, and GN4-CSF receptor-chain expression by cytokines: IL-3, IL-5, and GM-CSF receptor-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-S receptor expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor expression. J. Immunol. 170:5359-5366.
33. Ying, S., et al. 1999. Eosinophil chemoractic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoartractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics. J. Immunol. 163:6321-6329.
34. Hoshino, M., Nakamura, Y., Sim, J., Shimojo, J., and Isogai, S. 1998. Bronchial subepithelial fibrosis and expression of matrix metalloproreinase-9 in asthmatic airway inflammation. J. Allergy Clin. Immunol. 102:783-788.
35. Trifilieff, A., Fujitani, Y., Coyle, A.J., Kopf, M., and Bertrand, C. 2001. IL-S deficiency abolishes aspects of airway remodelling in a murine model of lung inflammation. Clin. Exp. Allergy 31:934-942.
36. Blyth, D.L., Wharton, T.F., Pedrick, M.S., Savage, T.J., and Sanjar, S. 2000. Airway subepithelial fibrosis in a murine model of atopic asthma: suppression by dexamethasone or anti-interleukin-5 antibody. Am. J. Respir. Cell Mol. Biol. 23:241-246.
37. Trigg, C.J., et al. 1994. Placebo-controlled immunopathologic study of four months of inhaled eorticosteroids in asthma. Am. J. Respir. Crit. Care Med. 150:17-22.
38. Ward, C., et al. 2002. Airway in flammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax. 57:309-316.
39. Zhang, H.Y., and Phan, S.H. 1999. Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am. J. Respir. Cell Mol. Biol. 21:658-665.
40. Desmouliere, A. 1995. Factors influencing myofibroblast differentiation during wound healing and fibrosis. Cell Biol. Int. 19:471-476.
41. Pearson, C.A., Pearson, D., Shibahara, S., Hofsteenge, J., and Chiquet-Ehrismanm R. 1988. Tenascin: cDNA cloning and induction by TGF-beta. EMBO J. 7:2977-2982.
42. Minshall, E.M., et al. 1997. Eosinophil-associated TGF-bera1 mRNA expression and airways fibrosis in bronchial asthma. Am. J. Respir. Cell Mol. Biol. 17:326-333.
43. Ohno, I., et al. 1996. Transforming growth factor beta 1 (TGF beta I) gene expression by eosinophils in asthmatic airway inflammation. Am. J. Respir. Cell Mol. Biol. 15:404-409.
44. Gizycki, M.J., Adelroth, E., Rogers, A.V., O'Byrne, P.M., and Jeffery, P.K. 1997. Myofibroblast involvement in the allergen-induced late response in mild atopic asthma. Am. J. Respir Cell Mol. Biol. 16:664-673.
45. Hakonarson, H., Maskeri, N., Carter, C., Chuang, S., and Grunstein, M.M. 1999. Autocrine interaction between IL-5 and IL-1beta mediates altered responsiveness of atopic asthmatic sensitized airway smooth muscle. J. Clin. Invest. 104:657-667.
46. Wiggs, B. R., Bosken, C., Pare, P.D., James, A., and Hogg, J.C. 1992. A model of airway narrowing in asthma and in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 145:1251-1258.
47. Chetta, A., et al. 1997. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest. 111:852-857.
48. Nishinakamura, R., Miyajima, A., Mee, P.J., Tybulewicz, V.L., and Murray, R. 1996. Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood 88:2458-2464.
49. Foster, P.S., et al. 2001. Elemental signals regulating eosinophil accumutation in the lung. Immunol. Rev. 179:173-181.
50. Sont, J.K., et al. 1999. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am. J. Respir. Crit. Care Med. 159:1043-1051.
51. Olivieri, D., et al. 1997. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am. J. Respir. Crit. Care Med. 155:1864-1871.
52. Hoshino, M., et al. 1998. Inhaled corricosreroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma. Clin. Exp. Allergy. 28:568-577.